Neuro / CNS
Companies whose principal business activity is classified as “Biotech - Neuro / CNS”.
Leadership as of 2026-10-27: Neutral. Relative to SPY: 5 sessions +5.7pp, 21 sessions −0.2pp, 63 sessions −13.3pp. Participation 43%; 7 of 10 members eligible.
- mixed or within ±0.5pp of SPY: no other rule holds
Economic family: Biotechnology
Member companies
- Biohaven Ltd. (BHVN)
- Achieve Life Sciences, Inc. (ACHV)
- Alkermes plc (ALKS)
- Neurocrine Biosciences, Inc. (NBIX)
- Praxis Precision Medicines, Inc (PRAX)
- Denali Therapeutics Inc. (DNLI)
- ACADIA Pharmaceuticals Inc. (ACAD)
- Ovid Therapeutics Inc. (OVID)
- Prothena Corporation plc (PRTA)
- Vanda Pharmaceuticals Inc. (VNDA)
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%